Picture6
Sanabit logo

SANABIT Technologies

Our medical devices uses safe levels of magnetic fields to stimulate the efficiency of the mitochondria for accelerating tissue closure and bone healing.

  • Stage Product In Development
  • Industry Healthcare Services
  • Location Rochester, NY, US
  • Currency USD
  • Founded June 2015
  • Employees 3
  • Incorporation Type C-corp
  • Website sanabit.org

Company Summary

Benefits of magnetic fields on the enhancement of mitochondrial efficiency were identified by Dr. Arthur Moss and others during ongoing clinical research. Our Minimum Viable Product (MVP) application of this effect is achieved through the integration and packaging of precision magnetic components into form factors suitable for accelerated tissue closure and/or bone healing devices. Our MVP can be expanded to PVD, Cardiology, Alzheimer’s.

Team

  • Ac769aec b14b 438d a25c e301fef62b9f
    Professor of Medicine, URMC

    Dr. Moss is a Professor of Medicine (Cardiology) and Founding Director of the Heart Research Follow-up Program at the University of Rochester School of Medicine and Dentistry in Rochester, New York. major areas of interest are in genetic and acquired heart rhythm disorders (arrhythmias), acute and chronic coronary heart disease, prevention of sudden cardiac death, clinical trials involving drugs and devices (ICD and CRT).

  • Default avatar
    Dr. Joseph Marasco
    COO

    Former CEO for Diffinity Genomics (developing novel tools for DNA purification) as well as Chiral Quest Corp. Before that as well as BD for Dow Comical and others. 35 years of technical and business leadership in the Biomedical devices community. Was CEO/President of four life-science firms, three of which he co-founded.

  • 2b7111dc 5b87 49e8 8aa8 47547aa782d2
    Professor of Medicine, Thomas Jefferson University

    Research objective is to elucidate an integrative mechanism by which mitochondria control intracellular Ca2+ homeostasis, energy metabolism, and reactive oxygen species (ROS) generation under both physiological and pathological conditions. Current research effort is to focus on the crosstalk Ca2+ signaling between mitochondria and sarcoplasmic reticulum during excitation-contraction coupling in normal and failing hearts.

  • Default avatar
    J. Montieth Estes
    Chief Investment Counsel

    J. Montieth “Monty” Estes concentrates his practice on advising emerging technology companies, including high tech start-ups, on legal and business issues, including how to develop and protect their intellectual property assets and how to secure stages of funding.

Advisors

  • Default avatar
    Jonathan S. Kahan, Partner, Hogan Lovells, FDA Liason
    Unconfirmed
    Default avatar
    Ilan Goldenberg, M.D.
    Unconfirmed
  • Default avatar
    Anne Schneiderman
    Unconfirmed
    Default avatar
    Dr. Salim Afshar DMD, MD
    Unconfirmed

Previous Investors

  • Default avatar
    J. Montieth Estes
    Unconfirmed